Choice of adjuvant drug therapy on the basis of the molecular classification of breast cancer
Molecular genetic analysis identified some biological subtypes of breast cancer (BC): luminal A, luminal B, HER2 positive, and basal-like (including triple negative). The surrogate clinical and morphological criteria including the immunohistochemical determination of estrogen and progesterone recept...
Saved in:
Main Author: | N. S. Besova (Author) |
---|---|
Format: | Book |
Published: |
ABV-press,
2014-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adjuvant Therapy for Endometrial Cancer in the Era of Molecular Classification
by: Sumedha Gupta, et al.
Published: (2024) -
A COMBINATION OF TAXOTERE, DOXORUBICIN, CYCLOPHOSPHOMIDE IN ADJUVANT CHEMOTHERAPY OF OPERABLE BREAST CANCER GRANULOCYTE COLONY-STIMULATING FACTORS PRIMARY PROPHYLAXIS
by: N. S. Besova, et al.
Published: (2014) -
Adjuvant therapy for early breast cancer
by: I. V. Vysotskaya
Published: (2014) -
Taxanes in adjuvant and neoadjuvant therapy for breast cancer
by: S. V. Limareva
Published: (2014) -
Potentialities of adjuvant endocrine therapy for breast cancer (Part II)
by: N. Yu. Dobrovolskaya, et al.
Published: (2014)